首页|Potential treatment approaches for malignant peritoneal mesothelioma:in vivo and in vitro experimental study of natural killer cell immunotherapy

Potential treatment approaches for malignant peritoneal mesothelioma:in vivo and in vitro experimental study of natural killer cell immunotherapy

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Objective:Malignant peritoneal mesothelioma(MPM)is a rare primary malignant tumor with an extremely poor prognosis that currently lacks effective treatment options.This study investigated the in vitro and in vivo efficacy of natural killer(NK)cells for treatment of MPM.Methods:An in vitro study was conducted to assess the cytotoxicity of NK cells from umbilical cord blood to MPM cells with the use of a high-content imaging analysis system,the Cell Counting Kit-8 assay,and Wright-Giemsa staining.The level of NK cell effector molecule expression was detected by flow cytometry and enzyme-linked immunosorbent assays.The ability of NK cells to kill MPM cells was determined based on live cell imaging,transmission electron microscopy,and scanning electron microscopy.An in vivo study was conducted to assess the efficacy and safety of NK cell therapy based on the experimental peritoneal cancer index,small animal magnetic resonance imaging,and conventional histopathologic,cytologic,and hematologic studies.Results:NK cells effectively killed MPM cells through the release of effector molecules(granzyme B,perforin,interferon-γ,and tumor necrosis factor-α)in a dose-and density-dependent manner.The NK cell killing process potentially involved four dynamic steps:chemotaxis;hitting;adhesion;and penetration.NK cells significantly reduced the tumor burden,diminished ascites production,and extended survival with no significant hematologic toxicity or organ damage in NOG mice.Conclusions:NK cell immunotherapy inhibited proliferation of MPM cells in vitro and in vivo with a good safety profile.

Malignant peritoneal mesotheliomanatural killer cellsimmunotherapycell immunotherapyintraperitoneal injection

Heliang Wu、Yi Wang、Yulin Lin、Ru Ma、Xuemei Du、Yandong Su、Rui Yang、Zhiran Yang、Xinli Liang、Yinguang Zhang、Xiaoqing Liang、Zhonghe Ji、Chunning Lai、Yajing Huang、Yan Li

展开 >

Department of Peritoneal Cancer Surgery,Beijing Shijitan Hospital,Peking University Ninth School of Clinical Medicine,Beijing 100038,China

Department of Peritoneal Cancer Surgery,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China

Department of Surgical Oncology,Beijing Tsinghua Changgung Hospital,Tsinghua University,Beijing 102218,China

Department of Hematology,Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China

Department of Thoracic Surgery,Zhongshan Hospital,Fudan University(Xiamen Branch),Xiamen 361015,China

Department of Pathology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China

Department of Thoracic Surgery,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China

Department of Oncology,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China

Innovvy Biomedical Technology Co.,Ltd.,Beijing 100195,China

展开 >

2024

10.20892/j.issn.2095-3941.2024.0218

癌症生物学与医学(英文版)
中国抗癌协会

癌症生物学与医学(英文版)

CSTPCD
影响因子：1.07
ISSN：2095-3941
年,卷(期)：2024.21(11)